NCT05268302View on ClinicalTrials.gov

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

January 4, 2024

Study Completion Date

January 4, 2024

Conditions
Dengue
Interventions
BIOLOGICAL

Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose

Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 0.

BIOLOGICAL

Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge

Low dose 0.5 mL of the challenge strain is administered subcutaneously in the triceps region of the arm on Study Day 366 in previously dosed participants.

Trial Locations (1)

21201

University of Maryland, Baltimore, Center for Vaccine Development and Global Health, Baltimore

All Listed Sponsors
collaborator

Medical Technology Enterprise Consortium (MTEC)

UNKNOWN

lead

University of Maryland, Baltimore

OTHER